Items where authors include "Ledermann, JA"

Article

Blagden, SP, Cook, AD, Poole, C et al. (16 more authors) (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. The Lancet Oncology, 21 (7). pp. 969-977. ISSN 1470-2045

Clamp, AR, James, EC, McNeish, IA et al. (26 more authors) (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet, 394 (10214). pp. 2084-2095. ISSN 0140-6736

González Martin, A, Oza, AM, Embleton, AC et al. (13 more authors) (2019) Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecologic Oncology, 152 (1). pp. 53-60. ISSN 0090-8258

Ledermann, JA, Embleton, AC, Raja, F et al. (16 more authors) (2016) Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 387 (10023). pp. 1066-1074. ISSN 0140-6736

Oza, AM, Cook, AD, Pfisterer, J et al. (21 more authors) (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncology, 16 (8). pp. 928-936. ISSN 1470-2045

Perren, TJ orcid.org/0000-0001-8472-8856, Swart, AM, Pfisterer, J et al. (23 more authors) (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New England Journal of Medicine, 365. pp. 2484-2496. ISSN 0028-4793

Adams, M, Calvert, AH, Carmichael, J et al. (20 more authors) (1998) Chemotherapy for ovarian cancer - a consensus statement on standard practice. British Journal of Cancer, 78 (11). pp. 1404-1406. ISSN 0007-0920